{"success":true,"data":{"pressRelease":{"id":"103738","rtpr_id":"nGNX9QnMJQ","ticker":"AIDX","exchange":"NASDAQ","all_tickers":["AIDX"],"title":"20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour","author":"Globe Newswire","published_at":"2026-07-30T12:31:00.096Z","article_body":"Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan\nParticipation and Strategic Meetings in Taipei, Tokyo, and Seoul\n\nWebinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time;\nRegistration Is Now Open\n\nGAITHERSBURG, Md., July 30, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc.\n(https://www.globenewswire.com/Tracker?data=AgJNGqEm0FQxXiN_gEjSikm7j9fU4EciduXHmgy7bMQY1C5mR-Di6Zpew3b52Q28xUuenGvZwloVCQ2eGfy8y4XfXGUhopHhWsC9_nVMcXU=)\n(Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market\nentrant in AI-powered, laboratory-based blood tests for the early detection\nand prevention of cancers and chronic diseases, today announced that it will\nhost an investor webinar on Wednesday, August 5, 2026, at 12:00 p.m. Eastern\ntime. Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, will discuss\nthe Company’s recent East Asia business development tour, including its\nparticipation in BIO Asia-Taiwan and strategic meetings held in Taipei, Tokyo,\nand Seoul, as well as the Company’s East Asia roll-up strategy.\n\nTo access the webinar, please use the following information:\n\n Date :     Wednesday, August 5, 2026                                                                                          \n Time:      12:00 p.m. Eastern time (9:00 a.m. Pacific time)                                                                   \n Webcast :  Please click here to register (https://us02web.zoom.us/webinar/register/WN_JLeuD8BIRUqWagGnXjhC5A#/registration).  \n                                                                                                                               \n\nDuring the webinar, management expects to address the following topics:\n* A recap of the Company’s participation in BIO Asia-Taiwan and its meetings\nwith companies, investors, laboratories, preventative health-check providers,\nand potential commercial partners in Taipei, Tokyo, and Seoul;\n* The Company’s East Asia roll-up strategy, including the merger,\nacquisition, licensing, joint venture, and commercial partnership\nopportunities it is evaluating in the region;\n* Why the Company believes that East Asia is a strategically important market\nfor protein biomarker-based cancer screening, routine health-check programs,\nand longitudinal laboratory testing;\n* How relationships in the region may support the Company’s technology\nplatform, data resources, and its goal of achieving Medicare reimbursement for\nmulti-cancer early detection (MCED) by the end of 2028;\n* Commercialization of OneTest™ for Cancer, OneTest™ for Longevity, and\nCLIAx, and the shared public company infrastructure model the Company intends\nto offer acquired or partnered businesses; and\n* A live question-and-answer session with management.\n“Our recent trip to East Asia reinforced our belief that the region can play\na meaningful role in 20/20 BioLabs’ international growth strategy,” said\nJonathan Cohen, Chief Executive Officer of 20/20 BioLabs. “We look forward\nto walking investors through what we saw and heard in Taipei, Tokyo, and\nSeoul, how those conversations fit into our roll-up strategy, and why we\nbelieve strategic acquisitions and partnerships in this region have the\npotential to strengthen our technology platform, expand our data resources,\nand accelerate commercialization.”\n\nThe August 5 webinar is part of the Company’s monthly investor webinar\nseries, held on the first Wednesday of each month at 12:00 p.m. Eastern time.\nInvestors and other interested parties are encouraged to submit questions in\nadvance to AIDX@mzgroup.us. A replay will be made available through the\nCompany’s investor relations website following the event.\n\nAs part of its commitment to expanding access to early cancer detection, 20/20\nBioLabs will provide webinar attendees with a promotional discount code for\nOneTest at the conclusion of the event. The offer will be available to all\nattendees, regardless of shareholder status.\n\nThere can be no assurance that the Company’s meetings in East Asia will\nresult in any definitive agreement, transaction, financing, commercial\nrelationship, or other strategic outcome. Any potential transaction would be\nsubject to customary due diligence, negotiation of definitive agreements,\nboard approval, regulatory considerations, and other conditions, and there can\nbe no assurance that any such potential transaction would be completed.\n\nAbout 20/20 BioLabs\n\n20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered,\nlaboratory-based blood tests for the early detection and prevention of cancers\nand chronic diseases. The Company offers two families of lab tests under the\nOneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or\nMCED, blood test, and OneTest™ for Longevity measures inflammatory\nbiomarkers and is commercially available. OneTest’s affordable, accurate,\naccessible tests can be conveniently utilized at home using new, upper-arm\ncapillary collection devices that avoid painful needles. Tests are run in the\nCompany’s College of American Pathologists (CAP) accredited, Clinical\nLaboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg,\nMaryland.\n\nFor more information visit https://2020biolabs.com.\n\nForward-Looking Statements\n\nCertain statements in this release are “forward-looking statements” within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended. These\nforward-looking statements involve known and unknown risks and uncertainties\nand are based on the Company’s current expectations and projections about\nfuture events that it believes may affect its financial condition, results of\noperations, business strategy, regulatory strategy, reimbursement strategy,\ngrowth strategy, acquisition strategy, and financial needs. Forward-looking\nstatements can be identified by words such as “may,” “could,”\n“will,” “should,” “would,” “expect,” “plan,” “intend,”\n“anticipate,” “believe,” “estimate,” “predict,”\n“potential,” “project,” “continue,” or the negative of these terms\nor other comparable expressions.\n\nForward-looking statements in this release include, but are not limited to,\nstatements regarding the Company’s planned investor webinar and the topics\nmanagement expects to address, its participation in BIO Asia-Taiwan, its\nmeetings in Taipei, Tokyo, and Seoul, its East Asia roll-up strategy,\npotential merger, acquisition, licensing, joint venture, commercial\npartnership, data, technology, laboratory, regulatory, reimbursement,\ncommercial, and growth opportunities, and the potential benefits of any such\nstrategy or transaction. Actual results may differ materially from those\nexpressed or implied by such forward-looking statements as a result of various\nfactors, including the risks described in the Company’s filings with the\nU.S. Securities and Exchange Commission, including the Company’s\nRegistration Statement on Form S-1, as amended, and other reports filed or\nfurnished from time to time with the SEC.\n\nThere can be no assurance that the Company will complete any acquisition,\nmerger, licensing arrangement, joint venture, commercial partnership,\nfinancing, regulatory submission, reimbursement milestone, or other strategic\ntransaction on any particular timeline, or at all. The Company undertakes no\nobligation to publicly update or revise any forward-looking statements to\nreflect events or circumstances that occur after the date of this release or\nto reflect the occurrence of unanticipated events, except as required by\napplicable law.\n\nInvestor Relations\nChris Tyson\nMZ Group\nDirect: 949-491-8235\nAIDX@mzgroup.us\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bcaf95ca-9983-408c-bc61-646e4ee2f925)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9QnMJQ","title":"20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour","author":"Globe Newswire","ticker":"AIDX","created":"2026-07-30T12:31:00.096Z","tickers":["AIDX"],"exchange":"NASDAQ","article_body":"Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan\nParticipation and Strategic Meetings in Taipei, Tokyo, and Seoul\n\nWebinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time;\nRegistration Is Now Open\n\nGAITHERSBURG, Md., July 30, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc.\n(https://www.globenewswire.com/Tracker?data=AgJNGqEm0FQxXiN_gEjSikm7j9fU4EciduXHmgy7bMQY1C5mR-Di6Zpew3b52Q28xUuenGvZwloVCQ2eGfy8y4XfXGUhopHhWsC9_nVMcXU=)\n(Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market\nentrant in AI-powered, laboratory-based blood tests for the early detection\nand prevention of cancers and chronic diseases, today announced that it will\nhost an investor webinar on Wednesday, August 5, 2026, at 12:00 p.m. Eastern\ntime. Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, will discuss\nthe Company’s recent East Asia business development tour, including its\nparticipation in BIO Asia-Taiwan and strategic meetings held in Taipei, Tokyo,\nand Seoul, as well as the Company’s East Asia roll-up strategy.\n\nTo access the webinar, please use the following information:\n\n Date :     Wednesday, August 5, 2026                                                                                          \n Time:      12:00 p.m. Eastern time (9:00 a.m. Pacific time)                                                                   \n Webcast :  Please click here to register (https://us02web.zoom.us/webinar/register/WN_JLeuD8BIRUqWagGnXjhC5A#/registration).  \n                                                                                                                               \n\nDuring the webinar, management expects to address the following topics:\n* A recap of the Company’s participation in BIO Asia-Taiwan and its meetings\nwith companies, investors, laboratories, preventative health-check providers,\nand potential commercial partners in Taipei, Tokyo, and Seoul;\n* The Company’s East Asia roll-up strategy, including the merger,\nacquisition, licensing, joint venture, and commercial partnership\nopportunities it is evaluating in the region;\n* Why the Company believes that East Asia is a strategically important market\nfor protein biomarker-based cancer screening, routine health-check programs,\nand longitudinal laboratory testing;\n* How relationships in the region may support the Company’s technology\nplatform, data resources, and its goal of achieving Medicare reimbursement for\nmulti-cancer early detection (MCED) by the end of 2028;\n* Commercialization of OneTest™ for Cancer, OneTest™ for Longevity, and\nCLIAx, and the shared public company infrastructure model the Company intends\nto offer acquired or partnered businesses; and\n* A live question-and-answer session with management.\n“Our recent trip to East Asia reinforced our belief that the region can play\na meaningful role in 20/20 BioLabs’ international growth strategy,” said\nJonathan Cohen, Chief Executive Officer of 20/20 BioLabs. “We look forward\nto walking investors through what we saw and heard in Taipei, Tokyo, and\nSeoul, how those conversations fit into our roll-up strategy, and why we\nbelieve strategic acquisitions and partnerships in this region have the\npotential to strengthen our technology platform, expand our data resources,\nand accelerate commercialization.”\n\nThe August 5 webinar is part of the Company’s monthly investor webinar\nseries, held on the first Wednesday of each month at 12:00 p.m. Eastern time.\nInvestors and other interested parties are encouraged to submit questions in\nadvance to AIDX@mzgroup.us. A replay will be made available through the\nCompany’s investor relations website following the event.\n\nAs part of its commitment to expanding access to early cancer detection, 20/20\nBioLabs will provide webinar attendees with a promotional discount code for\nOneTest at the conclusion of the event. The offer will be available to all\nattendees, regardless of shareholder status.\n\nThere can be no assurance that the Company’s meetings in East Asia will\nresult in any definitive agreement, transaction, financing, commercial\nrelationship, or other strategic outcome. Any potential transaction would be\nsubject to customary due diligence, negotiation of definitive agreements,\nboard approval, regulatory considerations, and other conditions, and there can\nbe no assurance that any such potential transaction would be completed.\n\nAbout 20/20 BioLabs\n\n20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered,\nlaboratory-based blood tests for the early detection and prevention of cancers\nand chronic diseases. The Company offers two families of lab tests under the\nOneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or\nMCED, blood test, and OneTest™ for Longevity measures inflammatory\nbiomarkers and is commercially available. OneTest’s affordable, accurate,\naccessible tests can be conveniently utilized at home using new, upper-arm\ncapillary collection devices that avoid painful needles. Tests are run in the\nCompany’s College of American Pathologists (CAP) accredited, Clinical\nLaboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg,\nMaryland.\n\nFor more information visit https://2020biolabs.com.\n\nForward-Looking Statements\n\nCertain statements in this release are “forward-looking statements” within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended. These\nforward-looking statements involve known and unknown risks and uncertainties\nand are based on the Company’s current expectations and projections about\nfuture events that it believes may affect its financial condition, results of\noperations, business strategy, regulatory strategy, reimbursement strategy,\ngrowth strategy, acquisition strategy, and financial needs. Forward-looking\nstatements can be identified by words such as “may,” “could,”\n“will,” “should,” “would,” “expect,” “plan,” “intend,”\n“anticipate,” “believe,” “estimate,” “predict,”\n“potential,” “project,” “continue,” or the negative of these terms\nor other comparable expressions.\n\nForward-looking statements in this release include, but are not limited to,\nstatements regarding the Company’s planned investor webinar and the topics\nmanagement expects to address, its participation in BIO Asia-Taiwan, its\nmeetings in Taipei, Tokyo, and Seoul, its East Asia roll-up strategy,\npotential merger, acquisition, licensing, joint venture, commercial\npartnership, data, technology, laboratory, regulatory, reimbursement,\ncommercial, and growth opportunities, and the potential benefits of any such\nstrategy or transaction. Actual results may differ materially from those\nexpressed or implied by such forward-looking statements as a result of various\nfactors, including the risks described in the Company’s filings with the\nU.S. Securities and Exchange Commission, including the Company’s\nRegistration Statement on Form S-1, as amended, and other reports filed or\nfurnished from time to time with the SEC.\n\nThere can be no assurance that the Company will complete any acquisition,\nmerger, licensing arrangement, joint venture, commercial partnership,\nfinancing, regulatory submission, reimbursement milestone, or other strategic\ntransaction on any particular timeline, or at all. The Company undertakes no\nobligation to publicly update or revise any forward-looking statements to\nreflect events or circumstances that occur after the date of this release or\nto reflect the occurrence of unanticipated events, except as required by\napplicable law.\n\nInvestor Relations\nChris Tyson\nMZ Group\nDirect: 949-491-8235\nAIDX@mzgroup.us\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bcaf95ca-9983-408c-bc61-646e4ee2f925)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-30T12:31:00.166949093Z","server_sent_at_ms":1785414660166},"received_at":"2026-07-30T12:31:00.218Z","source_url":"https://www.globenewswire.com/news-release/2026/07/30/3336071/0/en/20-20-biolabs-to-host-investor-webinar-on-august-5-2026-to-discuss-commercial-opportunities-following-management-s-recent-east-asia-business-development-tour.html"},"analysis":{"id":"92751","press_release_id":"103738","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"20/20 BioLabs scheduled an investor webinar for August 5, 2026, to review its recent business development tour through East Asia.\n\nThe session will detail the company's participation in BIO Asia-Taiwan and strategic meetings in Taipei, Tokyo, and Seoul, focusing on potential mergers, acquisitions, and licensing opportunities.\n\nManagement will also discuss commercialization efforts for OneTest for Cancer and OneTest for Longevity, alongside its goal to achieve Medicare reimbursement by the end of 2028.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine webinar discussing business development strategy."},"keyFigures":{},"quotedText":"Our recent trip to East Asia reinforced our belief that the region can play a meaningful role in 20/20 BioLabs’ international growth strategy","namedEntities":{"people":[{"name":"Jonathan Cohen","role":"Chief Executive Officer"},{"name":"Chris Tyson","role":"Investor Relations"}],"products":["OneTest™ for Cancer","OneTest™ for Longevity","CLIAx"],"companies":[{"name":"20/20 BioLabs, Inc.","ticker":"AIDX"},{"name":"MZ Group","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor webinar announcement regarding a business development trip. No definitive transactions, financial results, or material events disclosed."},"tickerRelevance":{"others":[],"primary":"AIDX"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_webinar"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"20/20 BioLabs scheduled an investor webinar for August 5, 2026, to review its recent business development tour through East Asia.\n\nThe session will detail the company's participation in BIO Asia-Taiwan and strategic meetings in Taipei, Tokyo, and Seoul, focusing on potential mergers, acquisitions, and licensing opportunities.\n\nManagement will also discuss commercialization efforts for OneTest for Cancer and OneTest for Longevity, alongside its goal to achieve Medicare reimbursement by the end of 2028.","key_figures":{},"named_entities":{"people":[{"name":"Jonathan Cohen","role":"Chief Executive Officer"},{"name":"Chris Tyson","role":"Investor Relations"}],"products":["OneTest™ for Cancer","OneTest™ for Longevity","CLIAx"],"companies":[{"name":"20/20 BioLabs, Inc.","ticker":"AIDX"},{"name":"MZ Group","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-30T17:44:05.288Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_webinar"}},"durationMs":76177,"modelName":"glm-4.7"}}